PHASE-II TRIAL OF ORAL VP-16-213 (ETOPOSIDE) IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER

被引：6
|
作者：
CRIVELLARI, D
VERONESI, A
MAGRI, MD
TIRELLI, U
COMORETTO, R
BARZAN, L
CARUSO, G
CARBONE, A
GRIGOLETTO, E
机构：
[1] CTR RIFERIMENTO ONCOL, DIV MED ONCOL, I-33081 AVIANO, ITALY
[2] CTR RIFERIMENTO ONCOL, DIV RADIOTHERAPY, I-33081 AVIANO, ITALY
[3] CTR RIFERIMENTO ONCOL, DIV PATHOL, I-33081 AVIANO, ITALY
[4] GEN HOSP, DIV OTOLARYNGOL, PORDENONE, ITALY
来源：
TUMORI JOURNAL | 1985年 / 71卷 / 05期
关键词：
D O I：
10.1177/030089168507100514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We tested VP16-213 in 16 patients with advanced head and neck cancer after conventional treatment. VP-16-213 was administered orally at the dosage of 100 mg/mq for 5 consecutive days every 3 weeks. No patient achieved an objective response. Toxicity was mild. VP-16-213 given at this dose and schedule revealed no activity in pretreated patients with head and neck cancer.
引用
收藏
页码：499 / 500
页数：2
相关论文
共 50 条
  • [1] RANDOMIZED PHASE-II TRIAL WITH VP-16-213(ETOPOSIDE) IN THE TREATMENT OF ADVANCED BREAST-CANCER
    CAVALLI, F
    JUNGI, WF
    BRUNNER, KW
    ONKOLOGIE, 1981, 4 (02): : 80 - 83
  • [2] PHASE-II STUDY OF ETOPOSIDE (VP-16) IN THE TREATMENT OF ADVANCED HEAD AND NECK-CANCER
    GRUNBERG, SM
    FELMAN, IE
    GALA, KV
    JOHNSON, KB
    OWENS, JC
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1985, 8 (05): : 393 - 395
  • [3] PHASE-II TRIAL OF ETOPOSIDE AND DOXORUBICIN IN ADVANCED HEAD AND NECK-CANCER
    GRADISHAR, WJ
    VOKES, EE
    KIES, MS
    MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (06): : 487 - 490
  • [4] PHASE-II CLINICAL-TRIAL OF VP-16-213 (ETOPOSIDE) ADMINISTERED ORALLY IN ADVANCED OVARIAN-CANCER
    HANSEN, F
    MALTHE, I
    KROG, H
    GYNECOLOGIC ONCOLOGY, 1990, 36 (03) : 369 - 370
  • [5] PHASE-II TRIAL OF VP-16-213 IN ADVANCED OVARIAN-CARCINOMA
    HILLCOAT, BL
    CAMPBELL, JJ
    PEPPERELL, R
    QUINN, MA
    BISHOP, JF
    DAY, A
    GYNECOLOGIC ONCOLOGY, 1985, 22 (02) : 162 - 166
  • [6] PHASE-II TRIAL OF ETOPOSIDE (VP16-213) IN ADVANCED PROSTATE-CANCER
    LOPRINZI, CL
    TRUMP, DL
    CLINICAL RESEARCH, 1984, 32 (02): : A418 - A418
  • [7] PHASE-II STUDY OF VP-16-213 (ETOPOSIDE) IN METASTATIC TRANSITIONAL CELL UROTHELIAL CANCER
    PONDER, BAJ
    OLIVER, RTD
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 12 (01) : 64 - 65
  • [8] PHASE-II TRIAL OF MITOGUAZONE IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER
    THONGPRASERT, S
    BOSL, GJ
    GELLER, NL
    WITTES, RE
    CANCER TREATMENT REPORTS, 1984, 68 (10): : 1301 - 1302
  • [9] A PHASE-II STUDY OF ORAL VP-16-213 IN PATIENTS WITH NON-SEMINOMATOUS TESTICULAR CANCER
    CAVALLI, F
    KLEPP, O
    RENARD, J
    HANSEN, HH
    ALBERTO, P
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 137 - 137
  • [10] ETOPOSIDE (VP-16-213) IN MALIGNANT BRAIN-TUMORS - A PHASE-II STUDY
    TIRELLI, U
    DINCALCI, M
    CANETTA, R
    TUMOLO, S
    FRANCHIN, G
    VERONESI, A
    GALLIGIONI, E
    TROVO, MG
    ROSSI, C
    GRIGOLETTO, E
    JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (05) : 432 - 437
12345